hit counter
Acasti Pharma Inc. (ACST) Stock News Sentiment & Price - Sentifly
ACST - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Acasti Pharma Inc. (ACST)

Canada
Biotechnology
NASDAQ
ACST Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACST Latest news
Newsfile Corp
Neutral
Acasti Pharma To Present At The Q4 Investor Summit on November 16th
2021-11-11 08:30

Laval, Quebec--(Newsfile Corp. - November 11, 2021) - Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) ("Acasti" or the "Company"), today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021. Jan D'Alvise, President and Chief Executive Officer of Acasti Pharma, is scheduled to present as follows:Event: Q4 Investor SummitDate and Time: Tuesday, November 16 at 3:30 pm Eastern TimeWebcast: https://us06web.zoom.us/webinar/register/WN_Wf9K_2n0QoO3WVYfML50_gA replay of the...

Seeking Alpha
Neutral
Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earning Call Transcript
2021-11-10 16:50

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earning Call Transcript

GlobeNewsWire
Neutral
Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call
2021-11-04 08:30

Call to be held on Wednesday, November 10th at 1:00 PM Eastern Time Call to be held on Wednesday, November 10th at 1:00 PM Eastern Time

GlobeNewsWire
Neutral
Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan
2021-10-06 08:30

Patents strengthen Acasti's IP portfolio and provide protection through 2036 and 2037, respectively Patents strengthen Acasti's IP portfolio and provide protection through 2036 and 2037, respectively

GlobeNewsWire
Neutral
Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage
2021-09-27 08:30

Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022 Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022

GlobeNewsWire
Neutral
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
2021-09-22 08:30

LAVAL, Québec, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq's minimum bid price requirement.

GlobeNewsWire
Neutral
Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21??
2021-09-14 08:30

LAVAL, Québec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.

The Motley Fool
Negative
Why Shares of Acasti Pharma Slumped Tuesday
2021-08-31 14:27

The clinical-stage pharmaceutical company completed its merger with Grace Therapeutics last week.

GlobeNewsWire
Neutral
Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split
2021-08-27 08:40

LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management's current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D'Alvise as President and Chief Executive Officer, under the oversight of Acasti's newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and com

PennyStocks
Positive
Are These Penny Stocks on Your Watchlist Right Now?
2021-08-12 09:47

Making a penny stocks watchlist in August? Check these 3 small-caps out The post Are These Penny Stocks on Your Watchlist Right Now?

Loading more news...